Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. - Wikidata - awgldk - TriplyDB

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.

http://www.wikidata.org/entity/Q37059782

about

Molecular classifications of gastric cancers: Novel insights and possible future applications.Genomic characterization of high-risk non-muscle invasive bladder cancer Immunotherapy for gastric cancers: emerging role and future perspectives.Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management.Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.Biomarkers for immunotherapy in bladder cancer: a moving target.Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.Tumor immunity and survival as a function of alternative neopeptides in human cancer.Novel Systemic Therapies for Advanced Gastric Cancer.Towards a better cancer precision medicine: systems biology meets immunotherapy.Immune checkpoint blockade therapy for esophageal squamous cell carcinoma.Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial Emerging Molecular Technologies in Genitourinary Tumors

P2860

Q33696201-D3AE8D28-0238-482C-8956-8D5BC1381074 Q37688916-AAE4739C-2A0D-4EE3-ABEB-506EF6C72A17 Q38738652-D8E1BD28-FB7C-42B8-8CB0-BB615C9ECFB3 Q40226483-E42B9C07-D65C-4DB0-BF8C-B16E3C2D79B3 Q46185591-B484F2D6-6FAC-4F4E-9396-5195403DFEDA Q46793262-4371BBEC-A89B-4E51-A561-980273D510C5 Q47382727-14ADA40D-A405-4139-AD82-8328D878E4B2 Q49246529-D5CA2156-5136-4041-AE71-CCF597A6713B Q49865882-D4E82168-C2AF-4F62-AED0-5393BD6BD493 Q50020805-01BCD86E-21C4-438B-A397-7AF642BF31A3 Q52599496-5E5D2F2F-93BD-43A3-88D5-1CEEC51D403E Q54967177-8E980C78-A701-45CC-8648-8B1AB4A8A9CF Q54968549-CB22EA32-5236-496E-B072-12E06C57F726 Q55457095-398B8253-329B-4748-AAAF-DB65FD9F4492 Q56891609-8593D1F9-E97B-4B8F-A0E1-C7E178EB7C64 Q57291659-2901A0A2-64C8-4F7F-B2F6-A6FA5860B994 Q57803796-F727FE67-EBD9-4108-944A-75BCF56BF46F Q58693931-48AF7670-57D2-418B-9D74-1DBFA1A46430

P2860

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.

http://www.wikidata.org/entity/Q37059782

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@en

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@nl

type

label

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@en

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@nl

prefLabel

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@en

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@nl

P1433

Q37059782-CEB992CF-ABBD-4BB8-B4D0-C33651FD7FD6

P1476

Q37059782-FF0B9A6F-7A15-4A79-B169-6382BCF1A15B

P2093

Q37059782-5AC0D45B-95A1-463C-BA7D-90D7849B360F

Q37059782-61D5784A-6472-403B-B1C8-7DD4CA9CC125

Q37059782-63214BE7-6491-43A3-BDE4-5972E53F07D6

Q37059782-7AD8485B-93EB-48A2-8113-1E11E7D6E6ED

Q37059782-9444C4AE-E733-4844-ADD7-A2291041A3BD

P2860

Q37059782-018B8F81-2284-48F1-B4CC-9D413245C543

Q37059782-0A214D55-BC82-46BB-8157-2AAD4D8CD74E

Q37059782-0CFA9C5D-00D1-4278-8CF1-4D0EB9B5AB83

Q37059782-1667699D-5F07-49CA-B80D-24DF7089E0F6

Q37059782-203DAA37-EDE6-4648-A572-18FCAF425C9A

Q37059782-25ED0B78-666E-42D2-BCF6-1D1E0D962497

Q37059782-2AD4482C-691C-41E3-BA43-9694D9CB921B

Q37059782-2BFFFC06-8BCA-47E0-A48A-4397F3E7DEC7

Q37059782-2E23C9D3-3F40-4CCE-96F1-A606BE34FF23

Q37059782-316005B3-48FF-4A81-8E17-1164A2144DF0

P304

Q37059782-710ADCDD-E64F-4E5C-9A2A-1806F4E9D319

P31

Q37059782-BAB21FFF-E71E-405E-9F02-A681C5AA8139

P356

Q37059782-17542FB1-F4E1-4403-A2F9-0E319690FADD

P407

Q37059782-D9188369-A60C-4AB1-BBE5-DD7578DF1FF0

P433

Q37059782-08C60840-EBAC-4CBF-BF3E-4816F19E57A8

P478

Q37059782-FFD615F1-41F4-482A-AFC6-98F650B97F82

P50

Q37059782-292C5E3A-5DB1-4D66-BE93-6CD5A1F3AC02

P577

Q37059782-2D273824-867B-4FDF-8C96-2FA9A546276B

P698

Q37059782-B862F87A-CB9B-455A-8DF5-7ADBCD76A4B2

P932

Q37059782-922D562B-3FE6-4E48-891C-E89F7817B4A5

P356

0008-5472.CAN-16-0170

P1433

Cancer Research

P1476

Burden of Nonsynonymous Mutati ...... heckpoint Inhibitor Responses.

@en

P2093

Kai Yu

http://www.w3.org/2001/XMLSchema#string

Lea Jessop

http://www.w3.org/2001/XMLSchema#string

Leandro M Colli

http://www.w3.org/2001/XMLSchema#string

Mitchell J Machiela

http://www.w3.org/2001/XMLSchema#string

Timothy A Myers

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

The Cancer Genome Atlas Pan-Cancer analysis project

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Melanoma genome sequencing reveals frequent PREX2 mutations

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

The genomic complexity of primary human prostate cancer

Immune Checkpoint Blockade in Cancer Therapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

P304

3767-3772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-16-0170

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Chanock

P577

2016-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27197178

http://www.w3.org/2001/XMLSchema#string

P932

4930685

http://www.w3.org/2001/XMLSchema#string